Last reviewed · How we verify
Apatinib Mesylate Tablets
Apatinib Mesylate Tablets is a Small molecule drug developed by Fujian Medical University. It is currently FDA-approved. Also known as: Aitan, AiTan, apatinib, YN968D1.
At a glance
| Generic name | Apatinib Mesylate Tablets |
|---|---|
| Also known as | Aitan, AiTan, apatinib, YN968D1, Ai Tan |
| Sponsor | Fujian Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer (PHASE2)
- A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) (PHASE2)
- Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD (PHASE2)
- Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer (PHASE3)
- A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation (PHASE3)
- Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma (PHASE2)
- Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer (PHASE3)
- BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apatinib Mesylate Tablets CI brief — competitive landscape report
- Apatinib Mesylate Tablets updates RSS · CI watch RSS
- Fujian Medical University portfolio CI
Frequently asked questions about Apatinib Mesylate Tablets
What is Apatinib Mesylate Tablets?
Apatinib Mesylate Tablets is a Small molecule drug developed by Fujian Medical University.
Who makes Apatinib Mesylate Tablets?
Apatinib Mesylate Tablets is developed and marketed by Fujian Medical University (see full Fujian Medical University pipeline at /company/fujian-medical-university).
Is Apatinib Mesylate Tablets also known as anything else?
Apatinib Mesylate Tablets is also known as Aitan, AiTan, apatinib, YN968D1, Ai Tan.
What development phase is Apatinib Mesylate Tablets in?
Apatinib Mesylate Tablets is FDA-approved (marketed).
Related
- Manufacturer: Fujian Medical University — full pipeline
- Also known as: Aitan, AiTan, apatinib, YN968D1, Ai Tan
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing